Helicon has identified Emergency Medicine, General and Cosmetic Surgery and Oncology markets as high potential segments in China and is seeking products with a strategic fit to the existing portfolio. More
APR is interested to in-license new early stage, innovative and patent protected products/technologies (preferably off patent or close to expiry) for oral, topical or transdermal administration More
Therapure Biopharma Inc. is seeking to license and/or acquire registered or late stage protein therapeutic products such as: plasma proteins, recombinant proteins, enzymes, monoclonal antibodies, sterile injectables More